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Abstract
Topoisomerases are expressed throughout the developing and adult brain and are mutated in some 
individuals with autism spectrum disorder (ASD). However, how topoisomerases are 
mechanistically connected to ASD is unknown. Here we found that topotecan, a Topoisomerase 1 
(TOP1) inhibitor, dose-dependently reduced the expression of extremely long genes in mouse and 
human neurons, including nearly all genes >200 kb. Expression of long genes was also reduced 
following knockdown of Top1 or Top2b in neurons, highlighting that each enzyme was required 
for full expression of long genes. By mapping RNA polymerase II density genome-wide in 
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neurons, we found that this length-dependent effect on gene expression was due to impaired 
transcription elongation. Interestingly, many high confidence ASD candidate genes are 
exceptionally long and were reduced in expression following TOP1 inhibition. Our findings 
suggest that chemicals and genetic mutations that impair topoisomerases could commonly 
contribute to ASD and other neurodevelopmental disorders.
Introduction
Autism is a neurodevelopmental disorder with symptoms that include repetitive behaviors 
and deficits in social interactions. Hundreds of genes are now associated with ASD1,2, 
suggesting there are diverse genetic risk factors for autism. Environmental factors, including 
chemicals that are ingested during critical periods of brain development3, can also increase 
autism risk. Many ASD candidate genes regulate synapse function4-6; however, whether 
there are additional mechanisms that unite ASD patients or expression of ASD genes is 
unclear.
Recently, we found that topoisomerase inhibitors can transcriptionally unsilence the paternal 
allele of Ube3a in neurons7. Ube3a is located adjacent to a cluster of imprinted genes, is 
normally expressed only from the maternal allele in neurons and regulates synaptic 
function8. In addition, Ube3a is associated with two distinct neurodevelopmental disorders. 
Specifically, deletion or mutation of maternal Ube3a causes Angelman syndrome while 
duplication of the chromosomal region containing maternal Ube3a is frequently detected in 
individuals with autism9,10.
Intriguingly, mutations in topoisomerases were recently identified in some individuals with 
ASD11,12. However, precisely how topoisomerases regulate expression of Ube3a and 
possibly other genes associated with autism is unknown. Topoisomerases, including Top1 
and Top2b, are expressed throughout the developing and adult brain13,14. Topoisomerases 
are integral to gene expression, as they resolve DNA supercoiling that is generated during 
transcription15-18. Here, we sought to determine if topoisomerases preferentially regulate 
expression of additional imprinted genes in neurons, or if topoisomerases have broader 
effects on gene expression. Using genome-wide approaches, we unexpectedly found that 
topoisomerases facilitate expression of long genes, including numerous long genes 
associated with synaptic function and ASD. In addition, our study uncovers a transcriptional 
mechanism that is particularly important for maintaining expression of numerous ASD 
genes at normal levels.
Gene length effects
To determine if topotecan, a TOP1 inhibitor, altered expression of imprinted genes, we 
treated cultured cortical neurons from C57BL/6J (B6) × CASTEi/J (CAST) F1 hybrid mice 
with vehicle or 300 nM topotecan, then used high-throughput transcriptome sequencing 
(RNA-seq) to survey changes in gene expression genome-wide. Single nucleotide 
polymorphisms (SNPs) were used to determine the parent-of-origin of sequence reads for 
autosomal genes19. We defined imprinted genes as those displaying statistically significant 
parent-of-origin expression bias in reciprocal C57/CAST crosses (Fisher’s exact test, P<0.05 
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after adjustment for multiple comparisons). We found that cortical neurons expressed 49 
known autosomal imprinted genes (Extended Data Table 1), yet Ube3a was the only 
imprinted gene that showed a significant change in parental allele bias in reciprocal crosses 
upon topotecan treatment (Fisher’s exact test, P<0.05 after correction; Extended Data Table 
1). Indeed, topotecan increased expression of the paternal allele of Ube3a, driving Ube3a 
levels significantly above wild-type levels (Extended Data Fig. 1a,b).
As we previously found7, topotecan reduced expression of Ube3a-ATS (Extended Data Fig.
1a,b). Ube3a-ATS is an extremely long (>1 Mb), paternally-expressed antisense-transcript 
that overlaps Ube3a and is required for paternal Ube3a silencing20,21. Other imprinted genes 
in the same genomic region as Ube3a did not show changes in allelic expression following 
topotecan treatment (Extended Data Fig. 1b, Extended Data Table 1). Importantly, topotecan 
also reduced expression of UBE3A-ATS and increased expression of UBE3A in induced 
pluripotent stem cell (iPSC)-derived neurons from an Angelman syndrome patient 
(Extended Data Fig. 1c). Topotecan thus had similar transcriptional effects at the Ube3a 
locus in mouse and human neurons.
Since Ube3a-ATS is extremely long and was strongly downregulated, we hypothesized that 
topotecan might reduce expression of other long genes. Remarkably, using RNA-seq and 
Affymetrix microarrays to quantify gene expression, we found that topotecan reduced 
expression of nearly all extremely long genes in mouse cortical neurons (Fig. 1a-c), with a 
strong correlation between gene length and reduced expression (for genes longer than 67 kb; 
Pearson’s R = −0.69). Topotecan also reduced expression of long genes in iPSC-derived 
human neurons (Fig. 1d). Topotecan did not exclusively reduce expression of extremely 
long genes, but instead acted over a continuum of gene lengths (Fig. 1c). Specifically, the 
percentage of genes that were inhibited (to any extent) by 300 nM topotecan increased from 
50% for genes 67 kb in length to nearly 100% for genes ~200 kb and longer. And, inhibition 
of long genes by topotecan was highly dose-dependent (Extended Data Fig. 2).
In contrast, topotecan increased expression of a majority of genes that were <67 kb in length 
(Fig. 1c), although the magnitude of this increase was very small for most genes (Fig. 1a,b). 
For some genes, this increase may reflect regulation by longer overlapping transcripts, like 
for Ube3a, or it might reflect other stimulatory effects of topoisomerase inhibitors22,23.
The length-dependent effects on gene expression were not due to cell death or persistent 
DNA damage, as topotecan (300 nM for 3 days) did not kill neurons or damage DNA 
(Extended Data Fig. 3a,b). Moreover, agents that damage DNA in neurons (paraquat and 
H2O2) did not reduce expression of long genes (Extended Data Fig. 3b-d). Notably, all 
length-dependent effects were fully reversible upon drug washout (Extended Data Fig. 3e), 
ruling out the possibility that gene expression changes were due to permanent effects (such 
as irreversible DNA damage and/or killing neurons).
A different TOP1 inhibitor, irinotecan, had a highly correlated length-dependent effect on 
gene expression in cortical neurons (Extended Data Fig. 4). Additionally, we re-analyzed 
published data from other labs and found that irinotecan and camptothecin (a TOP1 
inhibitor) strongly reduced expression of long genes and moderately increased expression of 
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shorter genes in several human cell lines (Extended Data Fig. 5a-e). Thus, the length-
dependent effects we observed were not unique to postmitotic neurons and could be 
reproducibly detected in expression data acquired by other labs.
We also found that lentiviral shRNA knockdown of TOP1 reduced expression of long genes 
in neurons (Fig. 2a,c), providing independent genetic support that TOP1 facilitates 
expression of long genes. These gene knockdown results also rule out the possibility that 
TOP1-DNA covalent complexes, which form only in the presence of TOP1 inhibitors18, 
block expression of long genes. Unlike TOP1 inhibitors (Fig. 1a-c, Extended Data Fig. 4a, 
Extended Data Fig. 5a-e), TOP1 knockdown did not globally increase expression of shorter 
genes (Fig. 2c). Thus TOP1 inhibitors likely increase expression of shorter genes via a drug-
specific effect that is unrelated to TOP1 depletion.
TOP2 enzymes (particularly TOP2B) also participate in gene transcription15,16,24. We next 
tested whether genetic or pharmacological inhibition of TOP2 enzymes could reduce the 
expression of long genes. Indeed, with new experiments and by re-analyzing data from 
others14,25, we found that the TOP2A/TOP2B inhibitor ICRF-193 reduced gene expression 
in a length-dependent manner in cultured mouse cortical neurons, embryonic stem (ES) 
cells, and ES cell-derived neurons (Extended Data Fig. 6a, Extended Data Fig. 7a,b). There 
was extensive overlap between genes affected by ICRF-193 and topotecan in cortical 
neurons, particularly for long genes, and the magnitudes of these effects were highly 
correlated (Extended Data Fig. 6b-e). Thus, TOP1 and TOP2 enzymes regulate expression 
of many of the same genes.
Since Top2b is the predominant TOP2 expressed in neurons25, we next knocked down 
Top2b with shRNA (Fig. 2b,d). We found that Top2b knockdown reduced expression of 
long genes (Fig. 2d). Moreover, re-analysis of published datasets showed that expression of 
long genes was reduced in embryonic brain and ES cell-derived neurons from Top2b−/− 
mice14 (Extended Data Fig. 7c,f,g). In contrast, long genes were expressed normally in 
Top2b−/− ES cells and neuronal progenitors25 (Extended Data Fig. 7d,e), presumably 
because these cell types express Top2a in addition to Top2b25. Lastly, two additional TOP2 
inhibitors (doxorubicin and etoposide) reduced expression of long genes in a human cancer 
cell line26 (Extended Data Fig. 5f,g). Together, our data show that TOP1 and TOP2 enzymes 
are both required for proper expression of long genes in mammalian cells. This stands in 
contrast to yeast, in which length-dependent transcriptional effects specific to TOP2 were 
observed27.
Length-dependent effect on elongation
Topoisomerases interact directly with RNA polymerase II (Pol II) and are required for 
transcription elongation17,28,29. To study genome-wide effects of topotecan on transcription 
in neurons, we measured Pol II distribution by chromatin immunoprecipitation followed by 
high-throughput DNA sequencing (ChIP-seq). We calculated the Traveling Ratio (TR) for 
all genes bound by Pol II, defined as the ratio of Pol II density (read counts per million 
mapped reads; RPM) near transcription start sites to Pol II density in the body of the gene, a 
parameter that is increased when transcription elongation is inhibited30-32. We found that 
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topotecan produced a distinct length-dependent increase in TR for very long genes, 
consistent with an impairment of transcription elongation (Fig. 3a, Extended Data Fig. 8).
The change in TR observed with topotecan treatment could reflect either a progressive 
inhibition of Pol II as it transcribes long genes, or it could reflect a block in the transition to 
productive elongation. To distinguish between these possibilities, we examined the change 
in Pol II density across the entire length of genes at high resolution (Fig. 3b). We found that 
Pol II density was slightly increased throughout the gene bodies of smaller genes, consistent 
with the modest increase in expression seen for smaller genes and with studies showing that 
TOP1 inhibitors can stimulate the transition to elongation of two genes (both shorter than 67 
kb)5,6. However, for longer genes, topotecan strongly reduced Pol II density across the 
entire length of the gene body (Fig. 3b). These results are consistent with topotecan affecting 
the transition to productive elongation at long genes. On average, all genes showed a slight 
increase in Pol II density in the promoter proximal region (Fig. 3c) and stronger increase in 
Pol II density near the transcription termination site (TTS; Fig. 3b). However, these changes 
were independent of length, making it unlikely that they contributed to differential 
expression of short versus long genes.
TOP1 inhibitors can stimulate the release of the positive elongation factor pTEF-B17. Thus, 
we next tested whether pTEF-B inhibition would affect expression of longer genes 
differently from shorter genes by treating neurons with 5,6-dichloro-1-β-D-
ribofuranosylbenzimidazole (DRB; a pTEF-B inhibitor that can block the transition to 
elongation17,30). We found that DRB (100 μM) reduced gene expression equally across all 
gene lengths (Fig. 3d), suggesting that the requirement for pTEF-B is not influenced by 
length. Note that 1 μM and 10 μM DRB had no length-dependent effects on expression (data 
not shown), ruling out the possibility that lower DRB concentrations preferentially impair 
expression of longer genes.
Numerous long ASD genes affected
To further investigate the biological consequences of TOP1 inhibition in neurons, we 
defined a list of genes that were differentially expressed with high confidence. From our 
RNA-seq expression data, we found that topotecan significantly downregulated 155 genes 
and significantly upregulated 28 genes (Benjamini-Hochtberg method, 5% false discovery 
rate) (Supplementary Data 1). The topotecan-downregulated genes were significantly longer 
(mean 591 kb, median 548 kb) than all expressed genes in cortical neurons (mean 59.3 kb, 
median 23.5 kb) and were significantly longer than topotecan upregulated genes (mean 29.3 
kb, median 16.4 kb) (One-way ANOVA vs. all expressed genes, P=2.2×10−16, vs. 
upregulated genes P=3.7×10−14), further indicating that topotecan has pronounced effects on 
long genes.
Based on Gene Ontology and functional annotation terms, we found that many topotecan-
downregulated genes were involved in neuronal development and synaptic function 
(Supplementary Data 2). Since ASD is thought to be a neurodevelopmental disorder that 
affects synapses, we cross-referenced our list of downregulated genes with known ASD 
candidate genes, combining genes in the SFARI Gene database with candidates identified in 
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recent exome sequencing studies11,12,33-35 (Supplementary Data 3). Remarkably, 27% 
(n=49) of the 183 differentially expressed genes are known ASD candidate genes (Table 1, 
Supplementary Data 3), a proportion that is highly significant compared to chance 
(P=4.4×10−8, Fisher’s Exact Test). Independent microarray experiments showed that these 
ASD genes were dose-dependently downregulated by topotecan (Extended Data Fig. 9). 
Notably, ASD candidate genes are exceptionally long as a group; genes in the SFARI Gene 
database (as of June 20, 2013) are 3.7-fold longer on average than all genes expressed in 
cortical neurons (means of 217.3 kb versus 59.3 kb). Thus, mutations that alter 
topoisomerase activity might reduce expression of numerous long ASD genes and might 
contribute significantly to ASD. Consistent with this hypothesis, recent sequencing studies 
of autism patient cohorts uncovered rare de novo missense mutations in TOP1, TOP3B, 
TOPORS (a TOP1-SUMO ligase36) and several other genes that directly connect to 
TOP111,12.
Discussion
Our study shows that topoisomerases facilitate expression of a large number of ASD 
candidate genes, including many that are long and that are thought to have large effects on 
ASD pathology in isolation1,2,37. Pharmacological inhibition of topoisomerases also reduced 
expression of long genes in other cell types, suggesting this length-dependent transcriptional 
effect is fundamental to all mammalian cells. Our data rule out numerous possibilities for 
why topoisomerase inhibitors reduce expression of long genes (e.g., cell death, DNA 
damage, formation of covalent complexes), and instead implicate a gene length-dependent 
block in transcription elongation. Pol II and topoisomerases dynamically form and remodel 
large supercoiling domains38, and the effects of topoisomerases on gene expression are 
strongly influenced by genomic structure and context23,39. Thus, we speculate that higher 
order structure differentially constrains shorter and longer genes, and that this creates 
distinct length-dependent requirements for topoisomerases in transcription elongation.
Some long genes were not strongly reduced in expression following topotecan treatment 
(Fig. 1a). In many cases this reflected ambiguity in gene annotation (data not shown). For 
example, a number of long genes also express shorter transcripts, making it difficult to 
distinguish expression of short isoforms from long isoforms. Alternatively, some long genes 
might be located within genomic regions that are more permissive for expression when 
TOP1 is inhibited.
Intriguingly, numerous genes associated with transcription are mutated in autism 
patients11,40,41, although how these diverse transcriptional regulators contribute to autism is 
unclear. Our study highlights a mechanistic link between a critical step in transcription 
elongation and expression of numerous long ASD candidate genes. Our data suggest that 
chemicals or genetic mutations that impair topoisomerases, and possibly other components 
of the transcription elongation machinery that interface with topoisomerases, have the 
potential to profoundly affect expression of long ASD candidate genes. Length-dependent 
impairment of gene transcription, particularly in neurons and during critical periods of brain 
development, may thus represent a unifying cause of pathology in many individuals with 
ASD and other neurodevelopmental disorders.
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Cortical neurons were cultured from E13.5-E15.5 mouse embryos as described7. For RNA-
seq and ChIP-seq, neurons were seeded on 10 cm diameter poly-D-lysine treated culture 
plates at a density of 5-10×106/plate. Microarray experiments used 6-well plates seeded at 
1×106 cells per well. After 7 days in culture, drugs or an equivalent amount of vehicle were 
added and left in the culture medium for 24 or 72 hours. For topotecan, irinotecan, DRB and 
paraquat; vehicle was 0.1% DMSO. For ICRF-193, vehicle was 0.02% DMSO.
Lentiviral shRNA experiments used viruses from The RNAi Consortium (acquired from 
Sigma-Aldrich and from the UNC Lenti-shRNA core): Top1 knockdown used clone 
TRCN0000011884 
(CCGGCCAGCGAAGATTCTATCTTATCTCGAGATAAGATAGAATCTTCGCTGG 
TTTTT) and Top2b knockdown used clone TRCN0000070988 
(CCGGCCTTGTGTTGTCCTTTGTCTTCTCGAGAAGACAAAGGACAACACAAGG 
TTTTTG). Virus expressing non-targeting hairpin RNA (SHC002, Sigma; 
CCGGCGTGATCTTCACCGACAAGATCTCGAGATCTTGTCGGTGAAGATCACG 
TTTTT) was used as a control. Neurons were seeded on 24-well plates at 2×105 per well. 
After 3 days in culture, cells were treated with lentivirus at a multiplicity of infection of at 
least 1. Virus was removed after 24 hours, and RNA harvested after a further 6 days in 
culture. Western blotting to assess knockdown was performed with anti-TOP1 (Santa Cruz 
Biotechnology, H5) or anti-TOP2B (Santa Cruz, H286) antibodies, with signal normalized 
to β-actin (Millipore, C4).
Cell death was assayed using Sytox Green (Invitrogen Molecular Probes). γH2AX foci were 
measured by immunohistochemistry. Primary antibodies were anti-γH2AX (Millipore, 1:500 
dilution) and anti-NeuN (Millipore, 1:500), used to mark neurons.
iPSC culture and neuronal differentiation
Human iPSC work was approved by the University of Connecticut Stem Cell Research 
Oversight Committee. iPSCs that carry a large deletion of maternal 15q11-q13 (AGdel1-0; 
see also (ref. 43), this cell line deemed exempt from IRB approval at the University of 
Connecticut due to its establishment in 1995 and lack of identifying information), were 
cultured on irradiated mouse embryonic fibroblasts and manually passaged as described43. 
iPSCs were differentiated into forebrain cortical neurons as described43 with the following 
modifications: neural progenitors were generated by culturing iPSCs on feeders in N2B27 
medium supplemented with Noggin (500 ng/mL) for 8 days and then manually picking 
neural rosettes for two additional passages using trypsin and standard cell culture protocols. 
Topotecan was applied to mature neurons and RNA was collected by standard protocols 6 
days following the addition of drug or vehicle.
King et al. Page 7














qRT-PCR was carried out as described43 using Taqman (Life Technologies) gene expression 
assays for UBE3A (Hs00166580_m1) and UBE3A-ATS (Hs03454279_m1) according to the 
manufacturer’s instructions. The Taqman assay for GAPDH was used as a control.
RNA-seq
Total RNA was collected using Trizol reagent (Invitrogen). Mouse polyA-selected mRNA 
libraries were then prepared using the Illumina True-Seq kit for RNA. For RNA-seq on 
human iPSC-derived neuronal samples, stranded multiplexed mRNA libraries were prepared 
using Illumina kits. Cluster generation and sequencing were performed using the Illumina 
HiSeq 2000 platform. For allele-specific expression analysis, equal amounts of total RNA 
from 3-6 biological replicates were pooled before polyA mRNA purification and library 
preparation.
For non-allelic expression analysis, data from an additional three biological replicates were 
included. mRNA was isolated and libraries prepared independently for each replicate 
sample. Library preparation incorporated barcoded adapters and all samples were sequenced 
in one lane, using 50 bp paired-end reads.
RNA-seq expression analysis
For allelic expression analysis, informative CAST/B6 SNPs were downloaded from (http://
www.sanger.ac.uk/resources/mouse/genomes/). CAST alleles were then substituted into 
their corresponding mm9 positions and sequence reads were aligned to mm9 and the CAST 
version of mm9 using Bowtie, selecting for unique matches. Filtered read counts for 
autosomal genes were tested for allelic bias using Fisher’s Exact Test against a background 
model derived from autosomes, and P-values adjusted for multiple comparisons using the 
Benjamini-Hochberg procedure. Statistical analysis was performed using R. Genomic 
intervals were derived from UCSC known genes or created manually where annotation was 
absent, namely for Ube3a-ATS.
For non-allelic analysis, reads were aligned to the reference genome (mm9) using Bowtie. 
Read counts were obtained using DEGseq, and normalization and analysis of differential 
gene expression was performed using the R package, edgeR, employing a negative binomial 
model.
ChIP-seq
ChIP-seq against RNA Pol II was performed as described previously30. Cultures (n=4/
condition) totaling approximately 2×107 neurons were treated with vehicle or 300 nM 
topotecan as described above. Nuclear lysates were sheared to an average fragment size of 
approximately 200 bp. 2 μg anti-RNA Pol II N20 (Santa Cruz Biotechnology) was added, 
and the sample incubated at 4°C for 16 hours. Chromatin immunoprecipitation was 
performed as described previously30,42
ChIP-seq libraries were prepared from immunoprecipitated samples and their corresponding 
inputs using the Illumina Tru-Seq kit for ChIP-seq. Ligation products were size-selected by 
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purification on 2% PippinPrep gels (Sage Science). Samples from vehicle and drug treated 
cells and their inputs were sequenced using the HiSeq 2000 platform with single-end reads 
of 50 bp.
ChIP-seq analysis
Short read sequences were aligned to the mouse reference genome (mm9) with Bowtie. 
Duplicate reads were removed. The quality of the experiment and false discovery rate for 
enriched peaks was assessed using MACS 1.4.2. CoverageBED was used to obtain read 
counts covering the promoter region (from −30 to +300 bp, relative to TSS and gene bodies 
(from +300 after TSS to 3000 bp after the annotated TTS, and to count reads in intervals 
across genes. Read counts were normalized to the number of mapped unique reads per 
sample (RPM) per base.
Affymetrix microarrays
For single-dose microarray experiments, cultured cortical neurons were treated with 300 nM 
or 1 μM topotecan, 10 μM irinotecan (Sigma) or 3 μM ICRF-193 (Santa Cruz 
Biotechnology), 100 μM DRB (Sigma), 100 μM H2O2 (Fisher Scientific), or 10 μM paraquat 
(Sigma) for 24 or 72 hours. For topotecan dose response, cells were treated with 3 nM, 30 
nM, 150 nM, 300 nM, 500 nM and 1000 nM topotecan or vehicle for 72 hours. Total RNA 
was used for all Affymetrix microarray experiments. Comparative expression with topotecan 
and ICRF-193 was measured with Affymetrix mouse genome 430 2.0 arrays. All other 
microarray experiments used Affymetrix Mouse Gene 1.0 ST 24-array plates. Linear RMA 
background correction and normalization was used for all microarray data.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. TOP1 inhibition reduces expression of long genes in neurons
a, Mouse cortical neurons treated with vehicle (v) or 300 nM topotecan (drug; d) for 3 days 
(n=5 biological replicates). RNA-seq gene expression versus gene length. b, Mean 
expression change in bins of 200 genes by length. c, Percentage of genes that were reduced 
in expression by topotecan; plotted as a sliding window of 100 genes by length, RNA-seq 
data (log scale). Inset, same data on linear scale. d, iPSC-derived human neurons treated 
with 1 μM topotecan for 6 days relative to vehicle, RNA-seq data in bins of 200 genes by 
length (n=2 biological replicates).
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Figure 2. Lentiviral shRNA knockdown of Top1 or Top2b in mouse cortical neurons reduces 
expression of long genes
a, b, Representative western blots and quantification of TOP1 and TOP2B seven days post 
infection. Normalized to β-actin in arbitrary units (A.U.). **P<0.01 relative to scrambled 
(Scr) control, Student’s t-test. Error bars, s.e.m. n=3 biological replicates. c, d, Gene 
expression from Affymetrix microarrays, relative to scrambled control shRNA. Plotted as 
mean expression change in bins of 200 genes by length.
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Figure 3. Topotecan impairs transcription elongation of long genes
a, Mouse cortical neurons treated with vehicle or topotecan (300 nM for 3 days). Pol II 
density in gene bodies and promoter regions, averaged for bins of 200 genes by length. b, c, 
Change in Pol II density across genes and (c) across the first 10 kb, averaged for groups of 
200 genes by length. Gene bins aligned relative to the transcription start site (TSS). d, 
Mouse cortical neurons treated with 100 μM DRB for 3 days. Affymetrix microarray 
expression compared to controls in bins of 200 genes by length.
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Table 1
Topotecan reduces expression of numerous ASD candidate genes in neurons







Cntnap2 * 2241.3 2304.6 −4.5718 0.0055 Yes H 275 R34
Csmdl 1642.8 2059.4 −3.4896 <0.0001 No Q 2254 R33
Nrxn3 1612.1 1460.7 −2.9494 <0.0001 Yes
Fhit 1611.9 1502.1 −2.1229 0.0490 Yes
Rbfoxl 1527.7 1694.2 −1.3178 0.0441 Yes
Grid2 1409.4 1468.1 −2.4100 0.0204 Yes
Illrapll 1368.4 1368.3 −3.0444 0.0213 Yes
Il1rapl2 1275.4 1200.8 −2.6076 0.0034 Yes
Park2 1223.0 1380.2 −2.8055 0.0003 Yes
Cntn5 1243.9 1337.9 −2.3360 0.0009 Yes
Ptprt 1133.5 1117.2 −2.0706 <0.0001 Yes
Frmpd4 1105.9 586.1 −1.5332 0.0028 Yes
Erbb4 1068.1 1162.9 −3.3890 <0.0001 Yes
Nrxn1 1059.2 1114.0 −2.1914 <0.0001 Yes Y 587 STOP12
Gpc6 1054.2 1181.2 −2.3530 <0.0001 Yes
Astn2 1023.7 989.8 −2.7763 0.0001 Yes
Cntn4 1021.6 959.1 −2.0717 0.0092 Yes
Pard3b 1003.5 1074.4 −2.9457 <0.0001 Yes
Epha6 952.0 934.3 −1.8366 0.0301 Yes
Grm7 921.6 880.4 −2.2647 <0.0001 No R 622 Q33
Nckap5 917.0 896.7 −1.3453 0.0089 Yes
Nlgnl 900.1 884.9 −1.8339 <0.0001 Yes H 795 Y34
Pcdh9 875.2 927.5 −1.8314 0.0002 Yes
Pcdh15 827.9 998.5 −3.2033 <0.0001 Yes
Grid1 761.0 766.9 −1.4922 0.0448 Yes
Mdga2 756.5 835.3 −1.6942 0.0012 Yes
Dpp10 713.4 1402.4 −1.7914 0.0007 Yes
Kcnmal 705.4 768.2 −1.9021 0.0004 Yes F 372 V11
Grik2 689.3 669.2 −1.5500 0.0028 Yes
Plcb1 689.1 752.3 −1.4067 0.0075 Yes
Ptprm 687.6 839.5 −1.7610 0.0057 No A 535 T12
Rbms3 679.7 729.1 −1.6432 0.0191 Yes
Vps13b 559.7 864.3 −1.0465 0.0317 Yes
Nbea 558.5 730.5 −1.3664 0.0147 Yes
Grm5 550.9 559.1 −1.3240 0.0343 Yes Aaa67912
Kalrn 545.0 626.5 −1.3646 0.0186 Yes
Ptprk 522.6 551.9 −1.6458 0.0005 No R 784 H34
Atrnll 522.3 855.3 −1.2194 0.0211 Yes
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Robo2 518.6 1712.5 −1.4921 0.0017 Yes
Cacna1c 515.9 644.7 −1.1665 0.0236 Yes
Lrrc7 477.8 363.3 −1.6330 0.0340 Yes
Reln 460.3 517.7 −2.0687 <0.0001 Yes Q 417 STOP
11
R 2290 C12
Exoc6b 451.0 646.7 −0.9691 0.0285 Yes
Gabrb1 437.2 395.2 −1.4909 0.0041 Yes
Nfia 341.3 385.5 −1.8218 0.0186 Yes R 30 STOP12
Nxph1 298.6 319.0 −1.8182 0.0181 Yes R 45 Q33
Myb 36.1 37.9 −3.8779 0.0011 No
C3 24.1 42.8 −2.2892 <0.0001 No I 1569 M11
C4b 15.5 1.7 −1.5240 0.0121 Yes
*
isoform a (uc009bst.2)
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